Audentes Therapeutics (BOLD) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Share on StockTwits

Audentes Therapeutics (NASDAQ:BOLD) issued its earnings results on Tuesday. The biotechnology company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.09), Briefing.com reports. During the same period last year, the business earned ($0.88) earnings per share.

NASDAQ:BOLD traded down $5.33 during mid-day trading on Wednesday, reaching $24.23. 3,418,753 shares of the stock were exchanged, compared to its average volume of 443,136. The company has a market capitalization of $1.10 billion, a PE ratio of -7.13 and a beta of 1.99. Audentes Therapeutics has a 1 year low of $19.62 and a 1 year high of $46.18.

In related news, CEO Matthew R. Patterson sold 21,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $38.16, for a total transaction of $801,360.00. Following the transaction, the chief executive officer now owns 17,144 shares in the company, valued at approximately $654,215.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Suyash Prasad sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $36.88, for a total value of $368,800.00. Following the transaction, the vice president now owns 100 shares in the company, valued at approximately $3,688. The disclosure for this sale can be found here. Insiders have sold a total of 77,039 shares of company stock worth $2,925,260 in the last 90 days. 6.60% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its stake in Audentes Therapeutics by 2.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 117,284 shares of the biotechnology company’s stock worth $4,644,000 after buying an additional 3,331 shares during the last quarter. Wells Fargo & Company MN grew its stake in Audentes Therapeutics by 7.9% during the 3rd quarter. Wells Fargo & Company MN now owns 429,678 shares of the biotechnology company’s stock worth $17,011,000 after buying an additional 31,523 shares during the last quarter. Victory Capital Management Inc. grew its stake in Audentes Therapeutics by 3.0% during the 3rd quarter. Victory Capital Management Inc. now owns 761,361 shares of the biotechnology company’s stock worth $30,142,000 after buying an additional 22,120 shares during the last quarter. Northern Trust Corp grew its stake in Audentes Therapeutics by 48.0% during the 2nd quarter. Northern Trust Corp now owns 368,571 shares of the biotechnology company’s stock worth $14,083,000 after buying an additional 119,602 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Audentes Therapeutics by 32.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 127,693 shares of the biotechnology company’s stock worth $4,879,000 after buying an additional 31,048 shares during the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

BOLD has been the topic of several research analyst reports. Zacks Investment Research raised Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Tuesday, July 10th. HC Wainwright set a $40.00 target price on Audentes Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 22nd. Mizuho reissued a “buy” rating and set a $45.00 target price on shares of Audentes Therapeutics in a research report on Wednesday, August 22nd. William Blair reissued a “buy” rating on shares of Audentes Therapeutics in a research report on Tuesday, August 7th. Finally, BidaskClub raised Audentes Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $36.00.

COPYRIGHT VIOLATION NOTICE: “Audentes Therapeutics (BOLD) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://weekherald.com/2018/11/07/audentes-therapeutics-bold-posts-quarterly-earnings-results-misses-expectations-by-0-09-eps.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: How are Outstanding Shares Different from Authorized Shares?

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply